clinical trial · NCT06024746
A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)
Colorado Prevention Center·phase3·recruiting·n = 1,500
Heart FailureFinerenoneEmpagliflozin
brief summary
Combination therapy of finerenone plus empagliflozin will be compared to usual care to determine the efficacy and safety of treatment in patients hospitalized with heart failure.
started
Jul 9, 2024
primary completion
Nov 1, 2027
completion
Nov 1, 2027
last updated
Sep 10, 2026
detailed description
This is an international, randomized, controlled, open-label, trial of an early, intensive management strategy using the combination of finerenone plus sodium-glucose co-transporter 2 inhibitor (SGLT2i) compared with usual care in patients hospitalized with heart failure (HF).
official title
Combined Efficacy and Safety of an Early, Intensive, Management Strategy With Finerenone and SGLT2 Inhibitor in Patients Hospitalized With Heart Failure (CONFIRMATION-HF)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol